ED50 of remidazolam toluenesulfonate in the disappearance of consciousness

Determination of ED50 of consciousness loss of remazolam toluenesulfonate in female patients by sequential test

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052835

Enrollment

Unknown

Registered

2021-11-06

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial polyps

Interventions

Experimental group:The test dose of rimazolom toluenesulfonate was given before anesthesia induction

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA I-II; 2. Patients undergoing gynecological hysteroscopy or cervical conization under general anesthesia with endotracheal intubation.

Exclusion criteria

Exclusion criteria: 1. The history of mental and neurological diseases; 2. Opioid and sedative drug dependence.

Design outcomes

Primary

Measure	Time frame
Heart rate;The patient's response to mandatory eye opening;Language increase, body movement, hiccup and so on;SPO2;Non-invasive blood pressure;	—

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 13563698838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026